BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript

🇺🇸 Seeking Alpha (US) —
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript

AI Summary

BeyondSpring discussed the FDA fast track designation and a strategic transaction relating to plinabulin for post-ICI non-squamous non-small cell lung cancer. The headline identifies a regulatory development and transaction but provides no further terms or clinical details.

Markets Deals Health BeyondSpring FDA fast track plinabulin lung cancer strategic transaction biopharmaceuticals

Read original source →